ABSTRACT
Globally, glaciers and icefields contribute significantly to sea level rise. Here we show that ice loss from Juneau Icefield, a plateau icefield in Alaska, accelerated after 2005 AD. Rates of area shrinkage were 5 times faster from 2015-2019 than from 1979-1990. Glacier volume loss remained fairly consistent (0.65-1.01 km3 a-1) from 1770-1979 AD, rising to 3.08-3.72 km3 a-1 from 1979-2010, and then doubling after 2010 AD, reaching 5.91 ± 0.80 km3 a-1 (2010-2020). Thinning has become pervasive across the icefield plateau since 2005, accompanied by glacier recession and fragmentation. Rising equilibrium line altitudes and increasing ablation across the plateau has driven a series of hypsometrically controlled melt-accelerating feedbacks and resulted in the observed acceleration in mass loss. As glacier thinning on the plateau continues, a mass balance-elevation feedback is likely to inhibit future glacier regrowth, potentially pushing glaciers beyond a dynamic tipping point.
ABSTRACT
OBJECTIVE: To assess whether clinical teams would direct patients to use web-based patient decision support interventions (DESIs) and whether patients would use them. DESIGN: Retrospective semistructured interviews and web server log analysis. PARTICIPANTS AND SETTINGS: 57 NHS professionals (nurses, doctors and others) in orthopaedic, antenatal, breast, urology clinics and in primary care practices across 22 NHS sites given access to DESIs hosted on the NHS Direct website. RESULTS: Fewer than expected patients were directed to use the web tools. The most significant obstacles to referral to the tools were the attitudes of clinicians and clinical teams. Technical problems contributed to the problems but the low uptake was mainly explained by clinicians' limited understanding of how patient DESIs could be helpful in clinical pathways, their perception that 'shared decision-making' was already commonplace and that, in their view, some patients are resistant to being involved in treatment decisions. External factors, such as efficiency targets and 'best practice' recommendations were also cited being significant barriers. Clinicians did not feel the need to refer patients to use decision support tools, web-based or not, and, as a result, felt no requirement to change existing practice routines. Uptake is highest when clinicians set expectations that these tools are integral to practice and embed their use into clinical pathways. CONCLUSIONS: Existing evidence of patient benefit and the free availability of patient DESIs via the web are not sufficient drivers to achieve routine use. Health professionals were not motivated to refer patients to these interventions. Clinicians will not use these interventions simply because they are made available, despite good evidence of benefit to patients. These attitudes are deep seated and will not be modified by solely developing web-based interventions: a broader strategy will be required to embed DESIs into routine practice.
ABSTRACT
Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties.
Subject(s)
Drug Discovery , Receptors, G-Protein-Coupled/agonists , Animals , Fluorine/chemistry , Humans , Inhibitory Concentration 50 , Mice , Molecular Structure , Niacin/chemical synthesis , Niacin/chemistry , Niacin/pharmacology , Pyridines/chemical synthesis , Pyridines/chemistry , Rats , Rats, Sprague-Dawley , Receptors, NicotinicABSTRACT
Hydrogen sulfide (H(2)S) is a recently discovered gasotransmitter found in mammalian tissues and blood. Treatment with H(2)S donor molecules has shown promising results in preclinical models of inflammatory and cardiovascular diseases. Augmentation of H(2)S levels thus holds promise as a novel therapeutic approach for treatment of disease in man. Cystathionine ß-synthase (CBS) has been shown to catalyze H(2)S production in vitro. CBS enzyme activity is allosterically regulated by the endogenous activator S-adenosyl methionine. This mode of regulation suggests the possibility for designing a small molecule activator of CBS to enhance H(2)S production. This hypothesis, however, has not been directly tested in vivo. We show here that CBS contributes significantly to endogenous H(2)S production in mice: adenovirus mediated over expression of CBS in the liver significantly increased circulating levels of H(2)S, whereas CBS deficiency resulted in reduced levels. We demonstrate that CBS enzyme from endogenous sources can be activated by S-adenosyl methionine to a greater extent compared to recombinant enzyme, suggesting greater potential for activation than previously anticipated. Importantly, we show that circulating H(2)S levels are increased by pharmacological activation of CBS in vivo; i.e. in the presence of the endogenous activator. Together, our data demonstrate that CBS activity partially regulates endogenous H(2)S in mice, and suggest that pharmacological activation of CBS is a promising approach for enhancing endogenous production of H(2)S for the treatment of cardiovascular and other diseases.
Subject(s)
Cystathionine beta-Synthase/genetics , Cystathionine beta-Synthase/metabolism , Genetic Engineering , Homocysteine/blood , Hydrogen Sulfide/blood , Adenoviridae/genetics , Animals , Enzyme Activation/drug effects , Humans , Male , Mice , Mice, Inbred C57BL , Mutation , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , S-Adenosylmethionine/pharmacologyABSTRACT
5-Alkyl and aryl-pyrazole-acids have been identified as a new class of selective, small-molecule, agonists of the human orphan G-protein-coupled receptor GPR109a, a high affinity receptor for the HDL-raising drug nicotinic acid.
Subject(s)
Pyrazoles/chemistry , Receptors, G-Protein-Coupled/agonists , Animals , Fatty Acids/metabolism , Humans , Mice , Niacin/chemistry , Pyrazoles/chemical synthesis , Pyrazoles/pharmacokinetics , Receptors, G-Protein-Coupled/metabolism , Receptors, Nicotinic/metabolismABSTRACT
A series of pyrazolyl propionyl cyclohexenamides were discovered as full agonists for the high affinity niacin receptor GPR109A. The structure-activity relationship (SAR) studies were aimed to improve activity on GPR109A, reduce Cytochrome P450 2C8 (CYP2C8) and Cytochrome P450 2C9 (CYP2C9) inhibition, reduce serum shift and improve pharmacokinetic (PK) profiles.
Subject(s)
Amides/chemistry , Cyclohexenes/pharmacology , Receptors, G-Protein-Coupled/agonists , Animals , Cyclohexenes/chemistry , Cyclohexenes/pharmacokinetics , Mice , Rats , Receptors, Nicotinic , Structure-Activity RelationshipABSTRACT
Niacin is an effective drug for raising HDL cholesterol. However, niacin must be taken in large doses and significant side effects are often observed, including facial flushing, loss of glucose tolerance, and liver toxicity. An anthranilic acid was identified as an agonist of the niacin receptor. In order to improve efficacy and provide structural diversity, replacements for the anthranilic acid were investigated and several compounds with improved properties were identified.
Subject(s)
Niacin/metabolism , Receptors, Drug/metabolism , ortho-Aminobenzoates/chemistry , Biological AvailabilityABSTRACT
Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR109A) agonists. Compound 1e (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.
Subject(s)
Carboxylic Acids/pharmacology , Cyclohexanecarboxylic Acids/pharmacology , Cyclohexenes/chemistry , Drug Discovery , Oxadiazoles/pharmacology , Receptors, G-Protein-Coupled/agonists , Animals , Area Under Curve , Binding, Competitive , CHO Cells , Carboxylic Acids/chemistry , Carboxylic Acids/pharmacokinetics , Cricetinae , Cricetulus , Cyclohexanecarboxylic Acids/chemistry , Cyclohexanecarboxylic Acids/pharmacokinetics , Dogs , Drug Evaluation, Preclinical , Fatty Acids, Nonesterified/blood , Humans , Metabolic Clearance Rate , Mice , Mice, Inbred C57BL , Mice, Knockout , Models, Chemical , Molecular Structure , Oxadiazoles/chemistry , Oxadiazoles/pharmacokinetics , Rats , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism , Receptors, Nicotinic/genetics , Receptors, Nicotinic/metabolism , Structure-Activity Relationship , Vasodilation/drug effectsABSTRACT
Global climate change will increase outdoor and indoor heat loads, and may impair health and productivity for millions of working people. This study applies physiological evidence about effects of heat, climate guidelines for safe work environments, climate modeling, and global distributions of working populations to estimate the impact of 2 climate scenarios on future labor productivity. In most regions, climate change will decrease labor productivity, under the simple assumption of no specific adaptation. By the 2080s, the greatest absolute losses of population-based labor work capacity (in the range 11% to 27%) are seen under the A2 scenario in Southeast Asia, Andean and Central America, and the Caribbean. Increased occupational heat exposure due to climate change may significantly impact on labor productivity and costs unless preventive measures are implemented. Workers may need to work longer hours, or more workers may be required, to achieve the same output and there will be economic costs of lost production and/or occupational health interventions against heat exposures.
Subject(s)
Climate Change , Efficiency , Models, Biological , Global Health , Humans , WorkloadABSTRACT
Label-free mass spectrometric (MS) technologies are particularly useful for enzyme assay design for drug discovery screens. MS permits the selective detection of enzyme substrates or products in a wide range of biological matrices without need for derivatization, labeling, or capture technologies. As part of a cardiovascular drug discovery effort aimed at finding modulators of cystathionine beta-synthase (CBS), we used the RapidFire((R)) label-free high-throughput MS (HTMS) technology to develop a high-throughput screening (HTS) assay for CBS activity. The in vitro assay used HTMS to quantify the unlabeled product of the CBS reaction, cystathionine. Cystathionine HTMS analyses were carried out with a throughput of 7 s per sample and quantitation over a linear range of 80-10,000 nM. A compound library of 25,559 samples (or 80 384-well plates) was screened as singlets using the HTMS assay in a period of 8 days. With a hit rate of 0.32%, the actives showed a 90% confirmation rate. The in vitro assay was applied to secondary screens in more complex matrices with no additional analytical development. Our results show that the HTMS method was useful for screening samples containing serum, for cell-based assays, and for liver explants. The novel extension of the in vitro analytical method, without modification, to secondary assays resulted in a significant and advantageous economy of development time for the drug discovery project.
Subject(s)
Cystathionine/analysis , Drug Discovery/methods , Drug Evaluation, Preclinical/methods , Animals , Calibration , Cell Line , Chromatography, High Pressure Liquid , Data Interpretation, Statistical , Dose-Response Relationship, Drug , Humans , Indicators and Reagents , Kinetics , Mass Spectrometry , Mice , Mice, Inbred C57BL , Spectrometry, Mass, Electrospray IonizationABSTRACT
Niacin is an effective drug for raising HDL cholesterol and reducing coronary risks, but patients show low compliance with treatment due to severe facial flushing upon taking the drug. A series of bicyclic pyrazole carboxylic acids were synthesized and tested for their ability to activate the niacin receptor. One analog, 23, showed improved potency and lacked flushing at doses that effectively altered the lipid profile of rats.
Subject(s)
Dyslipidemias/drug therapy , Hypolipidemic Agents/pharmacology , Niacin/pharmacology , Nicotinic Agonists/pharmacology , Pyrazoles/pharmacology , Animals , Cholesterol, HDL/metabolism , Fatty Acids, Nonesterified/metabolism , Hypolipidemic Agents/chemical synthesis , Hypolipidemic Agents/chemistry , Mice , Niacin/chemistry , Nicotinic Agonists/chemical synthesis , Nicotinic Agonists/chemistry , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Rats , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/metabolismABSTRACT
Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were discovered with excellent in vitro activity. Compound 2g displayed a good therapeutic index regarding free fatty acids (FFA) reduction and vasodilation effects in rats, with very weak cytochrome P450 2C8 (CYP2C8) and cytochrome P450 2C9 (CYP2C9) inhibition, and a good mouse pharmacokinetics (PK) profile.
Subject(s)
Cycloparaffins/chemical synthesis , Flushing/chemically induced , Heterocyclic Compounds, 3-Ring/chemical synthesis , Hypolipidemic Agents/chemical synthesis , Niacin/metabolism , Receptors, G-Protein-Coupled/agonists , ortho-Aminobenzoates/chemical synthesis , Adipocytes/drug effects , Adipocytes/metabolism , Animals , CHO Cells , Cricetinae , Cricetulus , Cycloparaffins/adverse effects , Cycloparaffins/pharmacology , Ear/blood supply , Heterocyclic Compounds, 3-Ring/adverse effects , Heterocyclic Compounds, 3-Ring/pharmacology , Humans , Hypolipidemic Agents/adverse effects , Hypolipidemic Agents/pharmacology , In Vitro Techniques , Lipolysis , Male , Mice , Radioligand Assay , Rats , Receptors, Nicotinic , Structure-Activity Relationship , Vasodilation/drug effects , ortho-Aminobenzoates/adverse effects , ortho-Aminobenzoates/pharmacologyABSTRACT
The discovery and structure-activity relationship of 1,2-diarylimidazole piperazine carboxamides bearing polar side chains as potent and selective cholecystokinin 1 receptor (CCK1R) agonists are described. Optimization of this series resulted in the discovery of isopropyl carboxamide 40, a CCK1R agonist with sub-nanomolar functional and binding activity as well as excellent potency in a mouse overnight food intake reduction assay.
Subject(s)
Anti-Obesity Agents/pharmacology , Benzodiazepines/pharmacology , Indoles/pharmacology , Obesity/drug therapy , Receptor, Cholecystokinin A/agonists , Thiazoles/pharmacology , Animals , Anti-Obesity Agents/chemical synthesis , Anti-Obesity Agents/chemistry , Benzodiazepines/chemical synthesis , Benzodiazepines/chemistry , Chemokines, CC , Humans , Indoles/chemical synthesis , Indoles/chemistry , Methylamines/chemical synthesis , Methylamines/chemistry , Methylamines/pharmacology , Mice , Piperazine , Piperazines/chemistry , Receptors, Cholecystokinin/agonists , Receptors, Cholecystokinin/chemistry , Thiazoles/chemical synthesis , Thiazoles/chemistryABSTRACT
High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was profiled extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities.
Subject(s)
Amides/chemical synthesis , Amides/pharmacology , Anti-Obesity Agents/chemical synthesis , Anti-Obesity Agents/pharmacology , Imidazoles/chemical synthesis , Imidazoles/pharmacology , Receptors, Cholecystokinin/agonists , Amides/chemistry , Animals , Anti-Obesity Agents/chemistry , Chemokines, CC , Combinatorial Chemistry Techniques , Eating/drug effects , Gallbladder Emptying/drug effects , Humans , Imidazoles/chemistry , Mice , Molecular Structure , Structure-Activity RelationshipABSTRACT
The design, synthesis, and biological activity of a series of cycloalkene acid-based niacin receptor agonists are described. This led to the discovery that tetrahydro anthranilic acid is an excellent surrogate for anthranilic acid. Several compounds were identified that were potent against the niacin receptor, had enhanced cytochrome P450 selectivity against subtypes CYP2C8 and CYP2C9, and improved oral exposure in mice.
Subject(s)
Cyclohexenes/chemical synthesis , Cyclohexenes/pharmacology , Cyclopentanes/chemical synthesis , Cyclopentanes/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Nicotinic Agonists/chemical synthesis , Nicotinic Agonists/pharmacology , ortho-Aminobenzoates/chemical synthesis , ortho-Aminobenzoates/pharmacology , Animals , Aryl Hydrocarbon Hydroxylases/drug effects , Cyclohexenes/chemistry , Cyclohexenes/pharmacokinetics , Cyclopentanes/chemistry , Cyclopentanes/pharmacokinetics , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP2C9 , Drug Design , Humans , Mice , Nicotinic Agonists/chemistry , Nicotinic Antagonists/pharmacology , ortho-Aminobenzoates/chemistry , ortho-Aminobenzoates/pharmacokineticsABSTRACT
Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.
Subject(s)
Receptors, G-Protein-Coupled/agonists , ortho-Aminobenzoates/chemical synthesis , Amides/chemical synthesis , Amides/pharmacokinetics , Amides/pharmacology , Animals , Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Binding, Competitive , CHO Cells , Cricetinae , Cricetulus , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP2C9 , Humans , In Vitro Techniques , Mice , Microsomes, Liver/metabolism , Radioligand Assay , Receptors, Nicotinic , Structure-Activity Relationship , ortho-Aminobenzoates/pharmacokinetics , ortho-Aminobenzoates/pharmacologyABSTRACT
INTRODUCTION: Compounds containing the carboxylic functional group (e.g. non-steroidal anti-inflammatory drugs) can be metabolized to form acylglucuronides. Acylglucuronides are intrinsically reactive metabolites capable of undergoing hydrolysis, intra-molecular rearrangement, and formation of covalent adducts with proteins, which may generate potential toxicity. The purpose of this study is to develop an in vitro screening model to assess degradation kinetics of acylglucuronides. METHOD: Zomepirac, ibuprofen, gemfibrozil, and compounds A, B, C, and D were incubated in the presence of rat microsomal protein and uridine 5'-diphosphoglucuronic acid (UDPGA), followed by addition of human plasma to evaluate degradation kinetics of the acylglucuronides. As a comparison, authentic acylglucuronide standards of zomepirac, ibuprofen, gemfibrozil, and compounds A, B, C, and D were chemically synthesized and were evaluated for degradation kinetics. RESULTS: The results demonstrate that degradation half-life values of acylglucuronides of zomepirac, ibuprofen, gemfibrozil, and compounds A, B, C, and D determined by the in vitro formation/degradation model were in the same rank-order with those of the authentic acylglucuronide standards. DISCUSSION: For the seven compounds tested, the model placed the stability of the acylglucuronides formed in vitro in a rank-order consistent with authentic acylglucuronide standards. The method allows for a rapid assessment of the stability of acylglucuronides.
Subject(s)
Glucuronides/chemistry , Animals , Drug Stability , Gemfibrozil/cerebrospinal fluid , Glucuronides/blood , Glucuronides/metabolism , Half-Life , Humans , Ibuprofen/cerebrospinal fluid , Male , Microsomes, Liver/metabolism , Models, Chemical , Rats , Tolmetin/analogs & derivatives , Tolmetin/chemistry , Uridine Diphosphate Glucuronic Acid/metabolismABSTRACT
BACKGROUND: Oregon law has allowed pharmacists to provide adult immunizations since 2000. Every vaccination delivered must be reported to the state health department. Previous reports indicate that pharmacists vaccinate individuals unlikely to receive vaccinations elsewhere. METHODS: Administration reports were analyzed in 2005 for the first three influenza seasons (2000 to 2003). The number of pharmacies participating, type and quantity of vaccinations, and county where provided were analyzed. RESULTS: A total of 13,116 adult patients received influenza vaccinations during 2000-2001 at 56 pharmacies. The number of pharmacies participating increased to 88 and 132, and vaccinations provided to 25,785 and 30,218 in the next two seasons, respectively. The mean number of vaccinations per pharmacy was 250 (standard deviation 236) for the 3-year period. Rural counties accounted for 28.4% of influenza vaccinations. CONCLUSIONS: Pharmacists provided a substantial number of influenza vaccinations during this 3-year period. More than one quarter of the vaccinations were provided in rural counties.
Subject(s)
Influenza, Human/immunology , Pharmacists , Vaccination/statistics & numerical data , Adult , Databases as Topic , Humans , Influenza, Human/prevention & control , Oregon , Professional RoleABSTRACT
To support in vivo screening efforts for estrogen receptor (ER) subtype selective therapeutic agents, we initiated work to discover surrogate markers (biomarkers) in blood plasma that would change in response to ER subtype-specific action. We used a proteomic approach employing strong anion exchange chromatography (SAX), PAGE, and MS to identify potential plasma markers for selective ER-alpha action. The methodology was used to compare blood from vehicle-treated rats to blood from rats treated with either 17beta-estradiol (an ER-alpha/ER-beta agonist) or compound 1 (17alpha-ethynyl-[3,2-c]pyrazolo-19-nor-4-androstene-17beta-ol, an ER-alpha-selective agonist). Blood samples were first fractionated by SAX to separate fractions containing dominant common plasma proteins from fractions enriched for less-abundant plasma proteins. 1-D PAGE analysis of fractions depleted of dominant plasma proteins revealed treatment-specific changes in protein profiles. Protein bands that changed reproducibly in response to ER-alpha action were excised from the gel, separated by capillary LC, and identified by microspray ESI-MS. Using this method, the plasma levels of two proteins, transthyretin and apolipoprotein E, were shown to decrease in response to ER-alpha agonism. The method lacked the sensitivity to identify the known, 1000-fold less-abundant, estrogenic marker prolactin (PRL). However, using a commercial RIA and immunoblots, we showed that PRL levels increase significantly in response to treatment with the ER-alpha selective agonist, compound 1.